Telehealth Program in Chronic Patients

Sponsor
Fondazione Salvatore Maugeri (Other)
Overall Status
Completed
CT.gov ID
NCT02269618
Collaborator
(none)
113
3
2
21
37.7
1.8

Study Details

Study Description

Brief Summary

The aim of this randomized control study is to determine the feasibility and efficacy of an innovative multidisciplinary telehealth program in chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) patients. 120 patients (1:1) will be included in the study and followed for 4 months and for additional 2 months of follow-up. The primary outcome is to improve tolerance capacity

Condition or Disease Intervention/Treatment Phase
  • Other: Home-based telehealth program
  • Other: Home-based rehabilitation
  • Other: Usual care
N/A

Detailed Description

COPD and CHF frequently coexist, causing a significant worsening in the quality of life of the patients and increasing morbidity and mortality. The prevalence of COPD in the CHF patients ranges from 20% to 32% of cases, and CHF is prevalent in more than 20% of patients with COPD.

COPD and CHF patients are complicated and frail with a high risk of re-hospitalizations; for this reason an individualized and multidisciplinary program need to be implemented in these patients. The chronic disease trend is fluctuating, burdened by many exacerbations through a vicious circle with dyspnoea, decreased activity, new exacerbations, depression and social isolation, leading to death.

The weight of evidence from a meta-analysis of randomized trials indicates that a multidisciplinary disease-management approach has the best outcomes in terms of prolonged survival and reduced hospital-readmission rates. Home-based management might, arguably, be the preferred approach after hospitalization of chronic diseases patients.

Home-base management might provide an opportunity to prevent clinical deterioration and hospitalizations by a comprehensive, long-term intervention with regular reinforcement of patient adherence, knowledge, and skills. A personalized hospital-discharge programme seems to be the best approach to plan the follow-up care of patients with chronic diseases.

These programmes, particularly important in the care of patients with multiple comorbidities, should include a routine self-management support, consisting in education to recognize symptoms early, to manage medical devices, to identify barriers to adherence to therapy such as adverse effects of drugs, and to check that the intensity of physical therapy is appropriate.

Our study want to investigate feasibility and efficacy of a multidisciplinary telehealth and tele-rehabilitation home based program in patients with COPD and CHF. This is an integrated, multidisciplinary nurse and therapist oriented program; these two figures have a central role during home based intervention and became an essential interface in the dialogue between patient and specialist. The nurse and therapist, each for their competence, collect information, carry out education and training, verify adherence to drug and physical therapy, verify the quality of caregiver assistance. When needed, they require intervention of specialist for consultation or second-opinion.

After drug therapy optimization and physical rehabilitation program definition, the patient will be allocated randomly into 2 groups: 1. Group A (usual care): the patients will be followed in the usual care manner by General Practitioner (GP) and routine specialist visits. 2. Group B (Home-based intervention): the patients will be monitored at home for 4 months by nurse and therapist and they will perform an individual rehabilitative program including at least 3 sessions/week of mini-ergometer and exercises and 2 sessions/week of walking with pedometer.

At baseline, after 4 months and further 2 months of follow-up all patients in both groups will undergo to follows clinical and physical evaluations:

  1. ECG (T0; T4 if needed)

  2. Echocardiogram (T0, T4 if needed

  3. Spirometry (T0 or a spirometry available in the previous year)

  4. Arterial blood gases (T0; T4)

  5. Walking test (T0; T4; T6)

  6. Metabolic Holter monitoring using the Body Monitoring Multi-Sensor Armband (BMSA) (SenseWear) worn at the triceps of the right arm for at least 72 h. (T0; T4; T6)

The questionnaires and scale :
  1. Minnesota (T0;T4;T6)

  2. COPD Assessment Test (CAT) (T0;T4;T6)

  3. Barthel (T0;T4;T6)

  4. Dyspnoea and muscle fatigue by Borg scale evaluation, referred by patient during his regular day (T0;T4;T6)

  5. Medical Research Council (MRC) scale for dyspnoea during regular day (T0;T4;T6)

  6. Physical activity scale for the elderly (PASE) (T0;T4;T6)

  7. Customer satisfaction (T4, only group B)

Study Design

Study Type:
Interventional
Actual Enrollment :
113 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Innovative Multidisciplinary Telehealth Program in COPD and CHF Patients: a Randomized Control Trial.
Study Start Date :
Jun 1, 2013
Actual Primary Completion Date :
Mar 1, 2015
Actual Study Completion Date :
Mar 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control group (Group A)

The patients will be followed in the usual care manner by GPs and by routine specialist visits, if needed

Other: Usual care
Usual care All patients will be followed also in usual care manner by their GPs.

Other: Intervention group (Group B)

Group B (Home-based intervention): the patients will be followed at home for 4 months by nurse and therapist and will perform an individual rehabilitative program. The interventions will be: Home-based telehealth program Home-based rehabilitation

Other: Home-based telehealth program
Home-based telehealth program Scheduled calls initiated by nurse performed weekly; the nurse carried out a standardized interview on general clinical condition of the patients. Unscheduled calls initiated by patients or caregivers through the service centre(24h/24h) to report any clinical problems. in case of signs or symptoms Telemonitoring: during calls, patients can transmit via landline or mobile phone the recordings from the 1-lead ECG to a service centre, and talk to the nurse or doctor Home visit performed by therapist seven days after hospital discharge by setting the daily physical activity and other home visits in case of need Scheduled calls initiated by therapist performed weekly aimed at increasing workload and evaluating the proper execution of exercises.

Other: Home-based rehabilitation
Home-based rehabilitation Individual rehabilitative program including at least 3 sessions/week of mini-ergometer and exercises and 2 sessions/week of walking with pedometer Mini-ergometer: The personalized protocol will be structured at the beginning on the basis of data obtained from the assessment of the baseline exercise test, trying to get a training activity to the maximum value of around a Borg dyspnoea and motor equal to 6 (according to the protocol of Maltais) Walking: The patient will be encouraged to walk every day. Will be given a pedometer and will be asked to try to increase the amount of steps up to the maximal for the patient.

Other: Usual care
Usual care All patients will be followed also in usual care manner by their GPs.

Outcome Measures

Primary Outcome Measures

  1. Improvement tolerance capacity [4 months and 6 months]

    The improvement in tolerance capacity will be measured by walking test performance (meters walked)

Secondary Outcome Measures

  1. Reduction of hospitalisations for cardiovascular disease and /or respiratory disease [4 months]

  2. Reduction of hospitalisations for all-cases [4 months]

  3. energy expenditure and duration and quantification of physical activity Energy expenditure and duration and quantification of physical activity [4 months and 6 months]

    The outcome will be measured in a subgroup of patients using metabolic holter monitoring using the Body Monitoring Multi-Sensor Armband (BMSA) (SenseWear) worn at the triceps of the right arm for at least 72 h.

  4. Improvement of quality of life [4 months]

    The improvement in quality of life, measured by Minnesota Questionnaire and CAT

  5. Reduction of clinical instabilities without hospital admission [4 months]

    The reduction of clinical instabilities will be measured by number of times that patients need to use antibiotics and/or corticosteroids and/or number of times that patients need to increase dosage of diuretic

  6. Reduction of impairment/disability [4 months]

    The reduction of impairment/disability will be measured with Barthel index

  7. Adherence to at least 70% proposal rehabilitative sessions [4 months and 6 months]

    The adherence will be calculated only in the group B

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • COPD new GOLD classification (B, C and D class) and a spirometry in the previous year and

  • Systolic and/or diastolic CHF defined at least by an echocardiogram performed in clinical stability; II, III and IV New York Heart Association class and optimized drug therapy.

  • Informed consent signed

Exclusion Criteria:
  • Physical activity limitations caused by non-cardiac and/or pulmonary problems

  • Obstructive Cardiomyopathies and/or myocarditis

  • Non cardiac and/or pulmonary pathologies that would cause the death of the patient during the study

  • Poor adherence and compliance of the patient

Contacts and Locations

Locations

Site City State Country Postal Code
1 FSM Respiratory Unit Lumezzane BS Italy 25066
2 Fondazione Salvatore Maugeri, Cardiology Unit Lumezzane BS Italy
3 Fondazione Salvatore Maugeri, Telemedicine Service Lumezzane BS Italy

Sponsors and Collaborators

  • Fondazione Salvatore Maugeri

Investigators

  • Study Chair: Michele Vitacca, MD, Fondazione Salvatore Maugeri

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Michele Vitacca, Responsible of Respiratory Unit, Fondazione Salvatore Maugeri
ClinicalTrials.gov Identifier:
NCT02269618
Other Study ID Numbers:
  • N.160
First Posted:
Oct 21, 2014
Last Update Posted:
Feb 8, 2016
Last Verified:
Feb 1, 2016
Keywords provided by Michele Vitacca, Responsible of Respiratory Unit, Fondazione Salvatore Maugeri
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 8, 2016